Helicos BioSciences Corporation Announces Pricing of Common Stock and Warrant Private Placement
CAMBRIDGE, Mass., Dec 19, 2008 (BUSINESS WIRE) -- Helicos BioSciences Corporation (NASDAQ: HLCS), a life science company focused on innovative genetic analysis technologies for the research, drug discovery, and diagnostic markets, today announced that it has entered into a definitive agreement with certain investors to raise approximately $18.6 million in gross proceeds in a private placement through the sale of shares of its common stock and warrants.
Ze-gen Secures $20 Million in Funding to Deploy Technology
Boston, MA – January 13, 2009 Ze-gen, Inc., which has developed commercially viable gasification technology for converting waste streams into synthesis gas, today announced that it has raised $20 million in Series B financing. The funds will be used to commercially deploy Ze-gen's technology.
Helicos Announces Improved Performance of Its HeliScope(TM) Single Molecule Sequencer
30GB of High-Quality Data at 150MB per Hour Throughput Equivalent to 5 to 10 Human Genomes is Industry Best
Black Duck Software Closes $9.5 Million in Financing
Capping year of solid growth, company will use funds for product enhancements and international expansion
Software Industry Veteran Tim Yeaton Named New CEO of Black Duck Software
Track record in open source software, successful partnerships and acquisitions strengthens Black Duck leadership position
Oasys Closes $10 Million Financing
Developing ultra-low cost seawater desalination and water treatment
Selecta Biosciences, Inc. Closes $15.1M Series B Financing
WATERTOWN, Mass.--(BUSINESS WIRE)--Selecta Biosciences, Inc., a privately held biopharmaceutical company developing immunomodulatory nanoparticles for the treatment and prevention of human diseases, announced today that it has secured a $15.1M Series B financing. Existing investors, Polaris Venture Partners and Flagship Ventures were joined by NanoDimension and Professor Timothy A. Springer. “I am pleased by the strength of our investors whose track record of creating successful companies is a loud validation of our team, technology platform, and product opportunities” said Dr.
Genstruct and Gene Logic Collaborate on Systems Toxicology
SAN FRANCISCO, Calif., CAMBRIDGE, Mass. and Gaithersburg, Md., February 25, 2009 – (CHI’s Molecular Medicine Tri-Conference) - Genstruct Inc., a systems biology company focused on identifying molecular mechanisms, networks and biomarkers to better develop novel therapeutics, molecular diagnostics and patient-specific therapies, today announced that it has signed a partnership agreement with Gene Logic, an Ocimum Biosolutions company, for a systems toxicology collaboration.
Mascoma Cellulosic Ethanol Plant Begins Operations in Rome, NY
Facility Generating Biomass-based Ethanol With Assistance from New York State Agencies
Boston, MA – February 25, 2009: Mascoma Corporation, a leader in the development of low carbon cellulosic ethanol, today announced that the company’s demonstration facility in Rome, New York, is now producing ethanol from non-food cellulosic biomass.
BG Medicine Appoints Doug White as Executive Vice President & General Manager, Diagnostics
Waltham, Mass. – BG Medicine Inc. (BGM) today announced that Doug White has joined the organization as Executive Vice President & General Manager, Diagnostics. In this newly created role, Mr. White will be responsible for the strategic direction and overall management of the company’s commercial operations as it advances a broad portfolio of high-value diagnostic tests toward commercial launch.